Peptika.
Cat. 06
Type I · Lyophilised
PK-2026-SEMAGL
Peptika Semaglutide vial
Lot-tracedEU pharmacyCold-chain 2–8 °C
N° 06 · Weight Management

Semaglutide.

GLP-1 receptor agonist for appetite regulation and glycemic control.

Select strengthPer-vial price
Quantity
1
Total
€70.00· 1 vial

Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.

  • ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
  • ✓Patient-named prescription only — dispensed against a valid Rx.
  • ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
  • ✓Cold-chain shipping across EU/EEA — 2–5 working days.
Overview

About Semaglutide.

Semaglutide is a long-acting GLP-1 receptor agonist with extensive Phase 3 evidence in type 2 diabetes (SUSTAIN programme) and obesity (STEP programme). It is the active ingredient of Ozempic, Wegovy and Rybelsus.

In magistral compounding, Semaglutide is prepared for individual patients when the licensed product is unavailable or unsuitable. The legal framework is identical to other Article 5(1) preparations; clinical effects mirror those of the licensed product.

Mechanism of action

Semaglutide is a structural analogue of native GLP-1 with substitutions that confer resistance to DPP-4 degradation and increase albumin binding. It binds the GLP-1 receptor on pancreatic β-cells (enhancing glucose-dependent insulin secretion), in the central nervous system (suppressing appetite via hypothalamic and brainstem pathways), and on gastric tissue (slowing emptying).

Posology · for information only

Subcutaneous injection, once weekly. Initiated at low dose (0.25 mg) with gradual titration over 16–20 weeks to a maintenance dose of 1.7–2.4 mg per week. Titration is essential to minimise gastrointestinal side effects.

Your physician sets the prescription. This is descriptive information, not a self-administration guide.

Storage

Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.

Evidence baseClinical RCT evidence
Indications studied
Type 2 diabetesObesityCardiovascular risk reduction
Selected references
  1. 01Wilding JPH, et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med · 2021 · doi: 10.1056/NEJMoa2032183
Identification & specifications
INN / Name
Semaglutide
Form
Lyophilised vial · subcutaneous injection
Strength
2mg vial
Manufacturing
EU-GMP Annex 1 · Grade A/B
Endotoxins
European Pharmacopoeia 2.6.14 · LAL assay
Identity & purity
HPLC + MS · > 98%
Cold chain
Validated 2–8 °C, monitored end-to-end
Regulatory basis
Directive 2001/83/EC · Article 5(1)
Logistics

2–5 working days

EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.

Legal status

Magistral preparation

Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.

Cross-border

EU prescription recognition

Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.

Same therapeutic axis

Within Weight Management.

All Weight Management preparations
Pre-compounded

Combinations with Semaglutide.